Meeting
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.
Authors
Claire F. Verschraegen
University of Vermont, Burlington, VT
Claire F. Verschraegen , Franklin Chen , David R. Spigel , Nicholas Iannotti , Edward Francis McClay , Charles H. Redfern , Jaafar Bennouna , Matthew H. Taylor , Howard Kaufman , Karen Kelly , Marcis Bajars , Anja von Heydebreck , Jean-Marie Cuillerot , Guy Heinrich Maria Jerusalem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01772004
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9036)
DOI
10.1200/JCO.2016.34.15_suppl.9036
Abstract #
9036
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.
First Author: Arun Rajan
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.
First Author: Andrea B. Apolo
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.
First Author: Karen Kelly
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: Safety and clinical activity.
First Author: Mary L. Disis